|  | Application No.                                   | Applicant(s)                 |
|--|---|------------------------------|
|  |   |                              |
| Notice of Allowability   | 09/910,406<br>Examiner                            | SOKAWA ET AL.                |
| •  |   |                              |
|  | Mary E. Mosher, Ph.D.                             | 1648                         |
| The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308. |   |                              |
| 1. This communication is responsive to 1/3/2005.   |   |                              |
| 2. The allowed claim(s) is/are <u>18-26</u> .  |   |                              |
| 3. The drawings filed on 19 July 2001 are accepted by the Examiner.  |   |                              |
| <ul> <li>4.  Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a)</li></ul>   |   |                              |
| Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.  THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.   |   |                              |
| 5. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.   |   |                              |
| 6. CORRECTED DRAWINGS ( as "replacement sheets") must be submitted.  |   |                              |
| (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review ( PTO-948) attached   |   |                              |
| 1)  hereto or 2)  to Paper No./Mail Date   |   |                              |
| (b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date   |   |                              |
| identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).  |   |                              |
| 7. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.  |   |                              |
| Attachment(s)  |   |                              |
| 1. Notice of References Cited (PTO-892)  |   | Patent Application (PTO-152) |
| 2. Notice of Draftperson's Patent Drawing Review (PTO-948)   | 6. ☐ Interview Summary<br>Paper No./Mail Da       |                              |
| 3. Information Disclosure Statements (PTO-1449 or PTO/SB/C Paper No./Mail Date   | Paper No./Mail Dai<br>08), 7. ⊠ Examiner's Amendr | ment/Comment                 |
| 4. Examiner's Comment Regarding Requirement for Deposit  |   | ent of Reasons for Allowance |
| of Biological Material   | 9.  | •                            |
|  | •   |                              |

Application/Control Number: 09/910,406

Art Unit: 1648

## **EXAMINER'S AMENDMENT**

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 1/3/2005 has been entered.

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Judy Mohr on March 11, 2005.

The application has been amended as follows:

In claim 18, at the end of line 2, "infected with hepatitis C virus (HCV)" has been inserted after "a human subject".

The following is an examiner's statement of reasons for allowance:

In the response filed 1/3/2005, independent claim 18 was amended to recite that the outcome of the treatment was a decrease in bloodstream ALT, and to raise the lower dosage limit to  $2 \times 10^8$  units per day. The maximum dose taught by Soos et al is "about  $1 \times 10^8$  units per day." Soos also broadly suggests treatment of HCV, but does not indicate that the treatment results in a decrease in ALT levels. There are indications

Application/Control Number: 09/910,406

Art Unit: 1648

in the prior art that interferons alpha and tau interact with the same receptor, suggesting similar biological activities, see for example Bazer et al US 5942223. However Zielinska et al (2 abstracts, newly cited) teaches an HCV treatment using oral interferon alpha, which did not appear to be particularly effective. Therefore, it is concluded that the prior art indicates less than a reasonable expectation of success at decreasing blood ALT levels in HCV patients using oral INF-tau, and does not provide particular motivation to exceed the maximum dosage taught by Soos.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

## Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Mary E. Mosher, Ph.D. whose telephone number is 571-272-0906. The examiner can normally be reached on M-T and alternate F.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Housel can be reached on 571-272-0902. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Page 4

Application/Control Number: 09/910,406

Art Unit: 1648

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

3/11/05

MARY E. MOSHER PRIMARY EXAMINER GROUP 1809